Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v2.4.1.9
Condensed Consolidated Statements of Operations (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Operating expenses:    
Research and development $ 723,430us-gaap_ResearchAndDevelopmentExpense $ 61,917us-gaap_ResearchAndDevelopmentExpense
General and administrative 811,869us-gaap_GeneralAndAdministrativeExpense 43,728us-gaap_GeneralAndAdministrativeExpense
Total operating expenses 1,535,299us-gaap_OperatingExpenses 105,645us-gaap_OperatingExpenses
Operating loss (1,535,299)us-gaap_OperatingIncomeLoss (105,645)us-gaap_OperatingIncomeLoss
Other expense:    
Interest expense (979)us-gaap_InterestExpense (11,163)us-gaap_InterestExpense
Interest income 560us-gaap_InvestmentIncomeInterest 45us-gaap_InvestmentIncomeInterest
Change in fair value of warrant liability   1,518us-gaap_FairValueAdjustmentOfWarrants
Foreign currency exchange loss   (734)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax
Other expense, net (419)us-gaap_NonoperatingIncomeExpense (10,334)us-gaap_NonoperatingIncomeExpense
Net loss $ (1,535,718)us-gaap_NetIncomeLoss $ (115,979)us-gaap_NetIncomeLoss
Net loss per share, basic and diluted $ (0.06)us-gaap_EarningsPerShareBasicAndDiluted $ (0.02)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average number of common shares outstanding, basic and diluted 25,871,796us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 6,964,788us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted